Europe Home Infusion Therapy Market Outlook & Forecast 2025–2033: Key

Europe Home Infusion Therapy Market Forecast 2025–2033

According to Renub Research Europe Home Infusion Therapy Market is projected to expand from US$ 13.08 billion in 2024 to US$ 21.85 billion by 2033, registering a strong CAGR of 5.87% between 2025 and 2033. Growth is driven by the rising prevalence of chronic diseases, rapidly aging populations, and growing demand for affordable, home-based medical treatments. Supportive European healthcare policies and the expansion of advanced infusion devices are further propelling market development across the region.

Europe Home Infusion Therapy Market Outlook

Home infusion therapy involves administering medications, nutrients, or fluids directly into a patient’s bloodstream through IV (intravenous) or subcutaneous routes in a non-hospital environment. It is prescribed under clinical supervision and commonly includes treatments such as:

·       IV antibiotics and antivirals

·       Chemotherapy and immunotherapy

·       Pain management solutions

·       Parenteral nutrition

·       Hydration therapy

·       Specialty pharmaceutical infusions

The purpose of home infusion therapy is to offer a safe, comfortable, and cost-efficient alternative to inpatient care. For patients with chronic diseases—including cancer, cardiovascular issues, autoimmune conditions, and long-term infections—home-based infusion significantly enhances quality of life, reduces travel requirements, limits exposure to hospital-acquired infections, and lowers overall healthcare costs.

As European healthcare systems shift toward decentralized care, home infusion therapy is becoming a key strategy in tackling hospital overcrowding and improving patient outcomes.

Request a free sample copy of the report:https://www.renub.com/request-sample-page.php?gturl=europe-home-infusion-therapy-market-p.php

Growth Drivers for the Europe Home Infusion Therapy Market

Growing Incidence of Chronic and Age-Related Disorders

Europe’s aging population is fueling greater incidence of diseases that require long-term IV therapy. Chronic illnesses—including cancer, diabetes, immunodeficiencies, kidney disease, and severe infections—create continuous demand for effective outpatient or home-based treatments.

Key statistics highlight the urgency:

·       85% of all deaths in the EU result from chronic diseases.

·       Cancer is the leading cause of mortality under age 65, while cardiovascular disease dominates mortality above 65.

Home infusion therapy enables safe delivery of prolonged treatments while allowing elderly patients to remain in familiar environments, improving adherence and long-term wellbeing.

Cost-Effectiveness and Reduced Hospital Burdens

Europe faces increasing pressure to reduce healthcare expenditures and hospital overcrowding. Home infusion therapy provides significant cost advantages:

·       Reduced hospital stay costs

·       Lower inpatient resource utilization

·       Decreased risk of hospital-acquired infections

·       Faster recovery in home environments

European governments and insurers support the shift to home care due to its economic benefits. The upcoming European centralized Health Technology Assessment system (2025) and 2023 EU pharmaceutical law reforms are expected to create an environment that favors innovative home-based therapies and devices.

Technological Advancements and Remote Monitoring

Innovations in portable infusion pumps, smart infusion devices, and telemonitoring solutions have dramatically improved treatment safety and patient convenience. Modern devices are lightweight, user-friendly, programmable, and equipped with features such as:

·       Wireless connectivity

·       Dose accuracy verification

·       Alarms and alerts

·       Automated flow control

Remote monitoring technologies enable healthcare providers to oversee patient progress in real time, intervene when necessary, and maintain high treatment standards without requiring hospital visits.

A notable development occurred in April 2022, when JMS Co., Ltd. received EU-MDR certification for its “JMS Tongue Pressure Measurement Device,” demonstrating Europe's openness toward innovative medical technologies.

Challenges in the Europe Home Infusion Therapy Market

Variability in Reimbursement and Regulatory Frameworks

Europe lacks uniform reimbursement policies for home infusion therapy. While countries like Germany and France provide strong financial support, others—especially in Eastern Europe—offer limited reimbursement. This inconsistency slows market expansion and creates barriers for multinational service providers.

Shortage of Skilled Healthcare Professionals

Home infusion therapy requires trained nurses and medical professionals for safe administration. Europe is facing:

·       Widespread nursing shortages

·       Limited availability of specialized home-care personnel

·       Workforce strains in rural areas

This shortage can lead to treatment delays, limited therapy options, and reduced patient satisfaction. Long-term solutions will require investments in training programs, digital support systems, and workforce expansion.

Europe Home Infusion Therapy Market by Segment

Europe Home Infusion Pump Market

Infusion pumps form the backbone of home infusion therapy. These pumps ensure accurate dosage delivery, safety, and mobility. Key features driving adoption include:

·       Lightweight portable designs

·       Programmable dosing

·       Smart pump connectivity

·       Enhanced drug-delivery precision

Increasing chronic disease cases, post-operative care needs, and advancements in pump technology continue to elevate demand across Europe.

Europe Home Infusion IV Cannulas Market

IV cannulas provide safe venous access essential for infusion therapy. Europe’s increasing rates of infections, cancer treatments, and immune disorder cases drive rising consumption of high-quality cannulas. Manufacturers are prioritizing:

·       Anti-contamination designs

·       Improved puncture safety

·       Comfortable, long-wear options

Expanded home-health services are accelerating demand for these essential consumables.

Europe Anti-Infective Home Infusion Therapy Market

Anti-infective therapy—particularly IV antibiotics—is the largest application segment. Home-based anti-infective therapy is widely used for:

·       Osteomyelitis

·       Cellulitis

·       Post-surgical infections

·       Pneumonia

·       Chronic wound infections

As antimicrobial resistance rises, demand for controlled, prolonged IV therapy at home continues to increase across Europe.

Europe Chemotherapy Home Infusion Therapy Market

Home-based chemotherapy is becoming increasingly common, especially for immunocompromised patients seeking safer alternatives to hospital visits. Benefits include:

·       Reduced exposure to infection

·       Increased comfort

·       Better treatment continuity

·       Reduced hospital visits

Countries such as France and the UK are developing national guidelines for delivering oncology treatments at home. Technological advancements in infusion pumps and remote monitoring support this transition.

Country-Level Insights

Germany Home Infusion Therapy Market

Germany has one of the strongest home infusion therapy ecosystems in Europe due to:

·       Comprehensive reimbursement

·       Advanced medical device adoption

·       Strong home-care services network

·       Skilled nursing workforce

Anti-infectives, parenteral nutrition, and pain management see significant adoption. Continued governmental focus on home healthcare modernization is aiding market expansion.

United Kingdom Home Infusion Therapy Market

The UK’s National Health Service (NHS) actively promotes home infusion to reduce inpatient load. Demand is strong for:

·       IV antibiotics

·       Oncology infusions

·       Hydration therapy

Technology adoption is accelerating, especially with the launch of BD neXus (May 2025), a next-gen infusion pump system introduced in the UK & Ireland.

Russia Home Infusion Therapy Market

Russia’s market is evolving with increasing home-care integration, particularly for chronic diseases. Challenges include:

·       Workforce shortages

·       Regional infrastructure gaps

However, modernization of healthcare services and rising public awareness point to strong long-term potential.

France Home Infusion Therapy Market

France has a mature and well-regulated home infusion ecosystem supported by:

·       Comprehensive national reimbursement

·       Collaboration between public hospitals and private infusion providers

·       High adoption of specialty pharmaceuticals

Anti-infectives, chemotherapy, and parenteral nutrition are among the leading therapy segments.

Market Segmentation

Product

·       Infusion Pumps

·       Intravenous Sets

·       IV Cannulas

·       Needleless Connectors

Application

·       Anti-Infective

·       Hydration Therapy

·       Chemotherapy

·       Enteral Nutrition

·       Parenteral Nutrition

·       Specialty Pharmaceuticals

·       Others

Country

France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Russia, Poland, Greece, Norway, Romania, Portugal, Rest of Europe

Key Companies Covered (5-Viewpoint Analysis)

·       Pfizer Inc.

·       Smith & Nephew plc

·       Terumo Corporation

·       Johnson & Johnson Services, Inc.

·       Becton, Dickinson and Company

·       Baxter International Inc.

·       ICU Medical

·       Eli Lilly and Company

(Each assessed via Overview, Key Person, Recent Developments, SWOT, Revenue Analysis)

Conclusion

The Europe Home Infusion Therapy Market is growing steadily as chronic diseases rise, aging populations expand, and healthcare systems shift toward cost-efficient, home-based models. Technological advancements—especially smart infusion pumps and telemonitoring—are making home infusion safer and more convenient than ever.

Despite challenges such as reimbursement variability and workforce shortages, Europe is expected to see strong market expansion through 2033 as governments, device manufacturers, and healthcare providers increasingly embrace decentralized treatment models.